|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NCI
|
The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process.
|
|
NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCI, NHLBI, NIBIB, NIEHS
|
The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government and industry with diverse interests.
|
|
NCI/CCR-FDA Clinical Investigator Program
|
Research Initiative
|
FDA
|
NCI
|
Create Multilateral Benefit in a Joint Program to Recruit Combined FDA and NCI/CCR Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind
|
|
NCI/CDC Cooperative Agreements for Cancer Control Activities in Low and Middle Income Countries
|
Other
|
CDC
|
NCI
|
NCI is partnering with CDC in Kenya and Indonesia to fund cancer control activities through the CDC cooperative agreement, via an interagency agreement between NCI/CGH and CDC. The activities that will take place under this agreement include cancer registry strengthening and related cancer control activities.
|
|
NCI/FDA Memorandum of Understanding for Drug Related Information
|
Resource Development
|
FDA
|
NCI
|
The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the U.S. Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 10,000 FDA terms and codes are stored in the NCI Thesaurus.
|
|
NCI/FDA Memorandum of Understanding for Proteomics
|
Research Initiative
|
FDA
|
NCI
|
This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between the NCI (Office of Cancer Clinical Proteomics Research) and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development.
|
|
NEI/FDA Symposium – Retina Outcome Variables
|
Meeting/ Workshop
|
FDA
|
NEI
|
This was a meeting held by FDA and NEI to develop outcome variables for use in clinical trials of drugs in retina diseases.
|
|
Nested Case-Controlled Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners
|
Research Initiative
|
CDC
|
NCI
|
A retrospective cohort mortality and nested case-control study of about 12,315 non-metal miners (278,041 person-years) to investigate risk of lung cancer in relation to quantitative measures of exposure to diesel exhaust.
|
|
Network Executive Committee for the NIAID Centers of Excellence for Influenza Research and Surveillance
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIAID
|
The Network Executive Committee is an advisory group to the NIAID/NIH on the management, integration and analysis of the Centers of Excellence for Influenza Research and Surveillance program. The Network Executive Committee consists of approximately 18 individuals including the contract Principle Investigators, NIAID staff and other federal and non-federal experts.
|
|
Networking and Information Technology Research and Development (NITRD)
|
Research Initiative
|
AHRQ
|
NIGMS
|
The NITRD Program provides a framework in which many Federal agencies come together to coordinate their networking and information technology (IT) research and development (R&D) efforts.
|